AstraZeneca forms drug delivery partnership; Aytu BioScience completes $5M financing round;

> AstraZeneca ($AZN) signed a licensing agreement with Starpharma enabling the development and commercialization of targets using the Australian company's drug delivery technology. AstraZeneca will pay Starpharma $2 million up front, and potentially more than $100 million in milestone payments based on product development, launch and sales levels. More

> Aytu BioScience announced that it has completed its private placement convertible note financing, raising $5.175 million in support of its orally disintegrating tablet that's formulated to treat premature ejaculation. More

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.